Yes, you may travel with RegLan provided you carry the prescription label and the original packaging. In the UK and most other countries, oral tablets are not considered prohibited items, and security scanners do not detect them. Keep the medication in your hand luggage to avoid temperature extremes.
Metoclopramide is not a prohibited substance on standard workplace or sport drug-testing panels. It will not produce a positive result for commonly screened drugs such as opioids, stimulants, or steroids. However, disclose all medications to the testing authority if required.
RegLan and Primperan contain the same active ingredient, metoclopramide 10 mg, and are bioequivalent. Differences may lie in inactive fillers, tablet colour, or manufacturer imprint codes, which do not affect therapeutic effect.
Metoclopramide is classified as Category B1 in the UK and may be used for severe nausea in early pregnancy under specialist advice. It is generally avoided after the first trimester because of a small risk of neonatal extrapyramidal symptoms.
Metoclopramide can increase serotonin levels and may theoretically raise the risk of serotonin syndrome when combined with SSRIs. This interaction is uncommon, but clinicians usually monitor patients for symptoms such as agitation, rapid heart rate, or sweating. Discuss any antidepressant use with your prescriber.
Prolonged exposure to dopamine antagonists raises the chance of developing tardive dyskinesia, an often irreversible movement disorder. The five-day limit balances efficacy for nausea while minimising this serious risk. Longer courses are only prescribed when benefits clearly outweigh risks and under specialist supervision.
For optimal pro-kinetic action, take RegLan 30 minutes before meals. This timing helps stimulate gastric emptying and reduces reflux. The tablet can be taken with a small amount of water; do not chew.
Store the pills in a cool, dry place away from moisture and direct sunlight. If humidity is high, keep the bottle inside a sealed plastic bag or a container with a desiccant packet (if provided) to maintain tablet integrity.
Generic metoclopramide tablets are typically priced lower than branded RegLan because they lack brand-specific marketing costs. Both contain the same 10 mg active ingredient and are interchangeable when prescribed. Prescription charges follow the standard NHS pricing structure.
Metoclopramide is approved for gastroparesis and may be prescribed for chronic cases when other therapies are insufficient. The NHS may cover RegLan if it is deemed clinically necessary, but individual funding decisions depend on the local Clinical Commissioning Group.
Metoclopramide is the active ingredient in RegLan, a 10 mg pill classified under Digestive Health medications. In the United Kingdom it is a prescription-only (POM) product regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Metoclopramide is marketed under several brand names, including RegLan, Primperan, and Maxolon.
Metoclopramide is a prokinetic agent that enhances gastrointestinal motility and exerts anti-emetic effects through several mechanisms:
The drug is rapidly absorbed after oral administration, reaching peak plasma concentrations within 1-2 hours. It is partially metabolised by the liver (CYP2D6) and excreted unchanged in the urine. The therapeutic effect usually begins within 30 minutes, with a duration of action of 4-6 hours.
Metoclopramide is approved by the MHRA for the following adult indications:
These uses reflect the drug’s ability both to speed gastric emptying and to block central vomiting pathways.
These effects are usually mild and transient. If they persist, contacting a healthcare professional is advisable.
Any sudden muscle rigidity, high fever, or uncontrolled movements warrant emergency medical attention.
Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and alcohol use before starting RegLan.
If a dose is missed and the next scheduled dose is more than 4 hours away, take the missed tablet. If it is soon time for the next dose, skip the missed one-do not double up.
Signs of overdose include extreme drowsiness, agitation, severe EPS, or hypotension. Management is supportive:
When stopping after short-term use, no taper is required. For prolonged therapy, gradual dose reduction (e.g., halve the dose every 2-3 days) helps prevent rebound nausea and reduces EPS risk.
If any alarming symptoms (e.g., uncontrolled muscle stiffness, fever) appear, seek urgent medical review.
This article provides educational information about RegLan (metoclopramide) and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
